Company intelligence / Profile preview

AT2B

Sophia Antipolis, France

Ownership: Private
Development stage: Other

Overview

AT2B is a French biotechnology company dedicated to developing innovative small molecule agonists of the Angiotensin II Type 2 Receptor (AT2R). The company focuses on the therapeutic potential of the protective arm of the renin-angiotensin system to treat chronic conditions such as neuropathic pain, inflammation, and fibrosis. Their lead candidates are designed to be highly selective for AT2R, offering a potential non-opioid mechanism for pain relief without the side effects associated with AT1 receptor activation. AT2B is currently advancing its pipeline through pre-clinical validation to address significant gaps in the current standard of care for chronic pain management.

Therapeutic areas: ImmunologyNeurologyOther
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on AT2B.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT2B.

Explore the full profile